ADC Ther­a­peu­tics has raised $550M-plus in its quest for their first BLA — and here’s why that’s im­por­tant

The mon­ey train con­tin­ues to chug in bio­phar­ma.

ADC Ther­a­peu­tics has added one last batch of cash to its E round — a 2-year fundrais­ing af­fair that is now be­ing closed at $303 mil­lion. The mon­ey will fund a dri­ve to their first planned BLA for their lead an­ti­body-drug con­ju­gate next year, with one piv­otal study ful­ly en­rolled and an­oth­er on the way.

ADC ini­tial­ly put to­geth­er a $200 mil­lion round for the piv­otal work, then added an ex­ten­sion that to­tals $103 mil­lion — slip­ping in $25 mil­lion from an un­named “U.S.-based in­sti­tu­tion­al in­vestor, as well as ad­di­tion­al in­vest­ment from ex­ist­ing in­vestors that par­tic­i­pat­ed in the pre­vi­ous­ly an­nounced $76 mil­lion Se­ries E fi­nanc­ing ex­pan­sion.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA